Efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy in virologically suppressed HIV-infected patients

Efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy in virologically suppressed HIV-infected patients - Efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy in virologically suppressed HIV-infected patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038177

Enrollment

120

Registered

2019-10-05

Start date

2019-03-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) HIV-infected patients who visited Kyushu-university hospital from January 1, 2013 to December 31, 2018. (2)Patients after switching TDF to TAF containing ART regimens in which virologically suppressed (HIV RNA< 20 copies/mL) for at least 6 months (3)Patients remain on the same third agent after switching to TAF/FTC containing regimen (4)Patients received an explanation of the study protocol and gave written informed consent. (5)Patients whose age is over 20 on informed consent acquisition date

Exclusion criteria

Exclusion criteria: Patients are inadequate to include in this study

Design outcomes

Primary

Measure	Time frame
Efficacy for maintenance of virological suppression in HIV-infected patients 48 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy.	—

Secondary

Measure	Time frame
Efficacy for improvement of renal function and bone metabolism markers, rate of new HBV infection 48 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy.	—

Countries

Japan

Contacts

Public ContactMasayuki Murata

Kyushu University Hospital Department of General internal medicine

mmurata@gim.med.kyushu-u.ac.jp092-642-5909

Outcome results